

# Uppsala Longitudinal Study of Adult Men

<https://www.neurodegenerationresearch.eu/survey/uppsala-longitudinal-study-of-adult-men/>

## Title of the cohort

Uppsala Longitudinal Study of Adult Men

## Acronym for cohort

ULSAM

## Name of Principal Investigator

Title Professor

First name Lars

Last name Lannfelt

## Address of institution where award is held

Institution Dept of Public Health and Caring Sciences/Geriatrics

Street Address

City Uppsala

Postcode 75185

## Country

- Sweden

## Website

[www.pubcare.uu.se/ULSAM](http://www.pubcare.uu.se/ULSAM)

## Contact email

[email protected]

## Funding source

### 1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias
- Neurodegenerative disease in general

### When studies on the above condition(s) are expected to become possible

- Already possible

### 2a. Stated aim of the cohort

Increased knowledge about the following disorders in an ageing population: cardiovascular and dementia disorders, diabetes, osteoporosis, nutrition and muscle function, and successful ageing

### 2b. Features distinguishing this cohort from other population cohorts

Over 40 years follow-up

**3a. i) Number of publications that involve use of cohort to date**

100

**3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**

**3b. Publication list/link to where data or publications are accessible (if available)**

**3c. Information (i.e. research findings) expected to be gained from the population cohort**

**4a. Study criteria: age range of participants at recruitment**

Age in years from: 50 years

To ('until death' if applicable): 90+/until death

**4b. Study criteria: inclusion criteria**

50-year old men living in Uppsala in 1970-1974

**4c. Study criteria: exclusion criteria**

None

**5. Size of the cohort (i.e. number of participants enrolled)**

- 1,000 – 5,000 participants

**6a. Measures used to characterise participants**

Vascular risk factors, specified dementia disorders, nutrition and muscle metabolism, detailed data on glucose and insulin metabolism, osteoporosis measurements, successful ageing

**6b. Additional measures for participants with a clinical disorder**

**6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

AD and other dementia disorders, death, stroke etc, successful ageing

**7. Study design**

- Prospective cohort

**8. Cases matched by**

Age

**9a. Does the study include a specialised subset of control participants**

- No

**9b. If yes, description of specialised subset of control participants**

**10a. i) Data collection start date**

01-01-1970

**10a. ii) Data collection end date**

**10a iii) Data collection for this study is**

- Data analysis ongoing

**10b. Plans to continue the cohort study beyond the current projected end date**

- No

**11. Data collected**

- Only through the study
- Through links to medical records
- Through links to other records or registers (such as dental records, police records etc). Please specify
  - Death register, National Inpatient Register

**12. System in place to enable re-contact with patients for future studies**

- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

**13a. Format and availability of data stored in a database**

**Language used:**

**13b. Format and availability of data held as individual records**

**Language used:**

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

**15. Data sharing policy specified as a condition of use**

- No requirement to make data publicly available

**16a. Are tissues/samples/DNA available to other groups**

Yes

**16b. i) Description of available tissues/samples/DNA**

- Living donors: DNA

**16b. ii) Form available tissues/samples/DNA are supplied in**

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

**17. Is information on biological characteristics available to other groups**

- No